Regeneron Pharmaceuticals traded at $590.59 this Friday July 1st, decreasing $0.54 or 0.09 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals lost 6.36 percent. Over the last 12 months, its price rose by 1.19 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 596.01 by the end of this quarter and at 549.20 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
590.59
Daily Change
-0.09%
Yearly
1.19%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Kyowa Hakko Kirin 3,035.00 -15.00 -0.49% -23.26%
Astellas Pharma 2,058.50 -56.50 -2.67% 6.99%
AbbVie 152.26 -0.89 -0.58% 32.20%
Agenus 1.87 -0.08 -3.87% -66.21%
Agios Pharmaceuticals 22.85 0.68 3.07% -59.00%
Alimera Sciences 5.45 -0.02 -0.37% -39.58%
Alnylam Pharmaceuticals 147.77 1.92 1.32% -13.80%
Amgen 243.70 0.40 0.16% -2.01%
AstraZeneca 10,754.00 -46.00 -0.43% 22.50%
Biogen 207.00 3.06 1.50% -40.64%
Bluebird Bio 4.13 -0.01 -0.24% -86.83%
BioMarin Pharmaceutical 83.29 0.42 0.50% -2.56%
Bristol-Myers Squibb 76.18 -0.82 -1.06% 13.79%
Esperion Therapeutics 6.25 -0.11 -1.73% -69.50%
Gilead Sciences 61.83 0.02 0.03% -10.78%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Intercept Pharmaceuticals 13.51 -0.30 -2.17% -32.42%
Incyte Corp 76.72 0.75 0.99% -8.21%
Ionis Pharmaceuticals 37.61 0.59 1.59% -5.79%
J&J 178.13 0.62 0.35% 5.41%
Eli Lilly 320.98 -3.25 -1.00% 37.19%
Merck & Co 91.56 0.39 0.43% 16.49%
Moderna Inc 149.36 6.51 4.56% -36.25%
Neurocrine Biosciences 98.27 0.79 0.81% -0.34%
Novartis 80.33 -0.52 -0.64% -4.96%
Novartis 83.41 -1.13 -1.33% -9.32%
Iveric bio Inc. 9.18 -0.44 -4.57% 15.62%
Opthea Ltd 1.20 0.10 8.64% -6.27%
Puma Biotechnology 2.73 -0.12 -4.21% -69.05%
Pfizer 51.85 -0.58 -1.11% 30.51%
Ultragenyx Pharmaceutical 61.86 2.20 3.69% -34.34%
Regeneron Pharmaceuticals 590.59 -0.54 -0.09% 1.19%
Roche Holding 320.40 1.85 0.58% -8.34%
Seattle Genetics 178.34 1.40 0.79% 13.40%
Sanofi 50.50 0.47 0.94% -3.57%
Sarepta Therapeutics 74.34 -0.62 -0.83% -1.20%
Teva Pharmaceutical Industries Ltd 2,670.00 -83.00 -3.01% -18.10%
United Therapeutics 235.05 -0.59 -0.25% 27.52%
Vertex Pharmaceuticals 283.70 1.91 0.68% 41.47%

Indexes Price Day Year
US500 3799 13.81 0.36% -12.72%
USND 11001 -28.15 -0.26% -24.86%
USNDX 11515 11.11 0.10% -21.81%

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.